Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia by Gu, Fangyi et al.
                          Gu, F., Zhang, H., & the ELLIPSE consortium (2017). Inherited variation in
circadian rhythm genes and risks of prostate cancer and three other cancer
sites in combined cancer consortia. International Journal of Cancer, 141(9),
1794-1802. https://doi.org/10.1002/ijc.30883
Peer reviewed version
Link to published version (if available):
10.1002/ijc.30883
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Wiley at http://onlinelibrary.wiley.com/doi/10.1002/ijc.30883/abstract. Please refer to any applicable terms of
use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
1 
 
Authors in the ELLIPSE consortium (Alphabetic order) 
Ali Amin Al Olama1, Demetrius Albanes2, Sara Benlloch3, Federico  Canzian4, Stephen J 
Chanock2, Constance  Turman5, Jenny L Denovan6, Doug Easton3, Ros Eeles7, Graham G Giles8, 
Edward  L Giovannucci5,9, Henrik Grönberg10, Christopher A Haiman11, Freddie C Hamdy12, 
Robert N Hoover1, David  J Hunter4, Tim J Key13, Laurence N Kolonel14, Zsofia Kote-Jarai6, 
Loic Le Marchand14, Sara Lindstrom5, Jing Ma5, Mitchell  Machiela2, David E Neal15, Elio 
Riboli16, Fredrick R Schumacher17, Afshan Siddiq18, Meir J Stampfer9, Victoria Stevens19, Ruth 
C Travis13, Fredrik Wiklund10, Jianfeng Xu20-21 
1Centre of Cancer Genetic Epidemiology, Department of Public Health and Primary Care, 
University of Cambridge, Cambridge, UK 
2Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA 
3School of Clinical Medicine, University of Cambridge, Cambridge, UK 
4Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, 
Germany 
5Department of Epidemiology, Harvard School of Public Health, Boston MA, USA 
6University of Bristol, Bristol, UK 
7American Cancer Society, Inc., Atlanta, GA, USA 
8Cancer Epidemiology Centre, Cancer Council Victoria Inc., Victoria, Australia 
9Department of Nutrition, Harvard TH Chan School of Public Health, Boston, MA, USA 
10Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, 
Sweden 
11Department of Preventive Medicine, Keck School of Medicine, University of Southern 
California, Los Angeles, CA, USA 
12Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK 
13Nuffield Department of Population Health, University of Oxford, Oxford, UK 
14Epidemiology Program, Cancer Research Center, University of Hawaii Cancer Center, Honolulu, HI, USA 
15Cambridge Clinical Trial Center & Oncology, University of Cambridge, Cambridge, UK 
16Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK 
2 
 
17Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA 
18Department of Genomics of Common Disease, School of Public Health, Imperial College London, London, UK 
19Institute of Cancer Research, London, UK 
20Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China 
21Program for Personalized Cancer Care, NorthShore University Health System, Evanston, IL, USA 
 
 
Additional Acknowledgement 
GECCO: The authors would like to thank all those at the GECCO Coordinating Center for 
helping bring together the data and people that made this project possible. The authors 
acknowledge Dave Duggan and team members at TGEN (Translational Genomics Research 
Institute), the Broad Institute, and the Génome Québec Innovation Center for genotyping DNA 
samples of cases and controls, and for scientific input for GECCO.   
ASTERISK: We are very grateful to Dr. Bruno Buecher without whom this project would not 
have existed. We also thank all those who agreed to participate in this study, including the 
patients and the healthy control persons, as well as all the physicians, technicians and students. 
DACHS: We thank all participants and cooperating clinicians, and Ute Handte-Daub, Utz 
Benscheid, Muhabbet Celik and Ursula Eilber for excellent technical assistance. 
HPFS, NHS and PHS: We would like to acknowledge Patrice Soule and Hardeep Ranu of the 
Dana Farber Harvard Cancer Center High-Throughput Polymorphism Core who assisted in the 
genotyping for NHS, HPFS, and PHS under the supervision of Dr. Immaculata Devivo and Dr. 
David Hunter, Qin (Carolyn) Guo and Lixue Zhu who assisted in programming for NHS and 
HPFS, and Haiyan Zhang who assisted in programming for the PHS. We would like to thank the 
participants and staff of the Nurses' Health Study and the Health Professionals Follow-Up Study, 
for their valuable contributions as well as the following state cancer registries for their help: AL, 
AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, 
NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full 
responsibility for analyses and interpretation of these data. 
PLCO: The authors thank Drs. Christine Berg and Philip Prorok, Division of Cancer Prevention, 
National Cancer Institute, the Screening Center investigators and staff or the Prostate, Lung, 
Colorectal, and Ovarian (PLCO) Cancer Screening Trial, Mr. Tom Riley and staff, Information 
Management Services, Inc., Ms. Barbara O’Brien and staff, Westat, Inc., and Drs. Bill Kopp and 
staff, SAIC-Frederick.  Most importantly, we acknowledge the study participants for their 
contributions to making this study possible. The statements contained herein are solely those of 
the authors and do not represent or imply concurrence or endorsement by NCI. 
PMH: The authors would like to thank the study participants and staff of the Hormones and 
Colon Cancer study. 
3 
 
WHI: The authors thank the WHI investigators and staff for their dedication, and the study 
participants for making the program possible. A full listing of WHI investigators can be found at: 
http://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator
%20Short%20List.pdf 
 
 
4 
 
 
5 
 
Supplementary Table 1. Population and design of each contributed study 
Cancer Study Locations Design 
Initial analytical data in GAME-ON 
Colon & Rectum MECC US Cohort 
(CORECT) CFR US Cohort 
 Kentucky US Pop. CC 
 CPS-II/ACS US Cohort 
 Melbourne Australia Cohort 
 Newfoundland  Canada Pop. CC 
    
Lung MDACC US Hospital CC 
(TRICL) ICR UK Hospital CC 
 Toronto Canada Clinic CC 
 IARC Europe Hospital CC 
 GLC German Pop. CC 
 NCI US Pop. CC and nested CC 
    
Ovary UKGWAS UK CC 
(FOCI) USGWAS US, Canada, Poland CC 
 U19 US CC 
    
Prostate BPC3 US CC, nested CC 
(ELLIPSE) CRUK1 UK CC 
 CRUK2 UK CC 
 CAPS1 Sweden CC 
 CAPS2 Sweden CC 
    
Replication data    
Prostate (PLCO) PLCO US Nested CC 
    
Colon & Rectum    
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CC: case-control 
 
  
(GECCO) ASTERISK  France Hospital CC 
 COLO23   US Pop. CC 
 DACHS1    Germany Pop. CC 
 DACHS2    Germany Pop. CC 
 DALS1     US Pop. CC 
 DALS2  US Pop. CC 
 HPFS1     US Nested CC 
 
HPFS2 
US Nested CC 
 HPFSad    US Nested CC 
 MEC       US Nested CC 
 NHS1     US Nested CC 
 NHS2      US Nested CC 
 NHSad     US Nested CC 
 OFCCR  Canada Pop.CC 
 PHS1P2 US Nested CC 
 PLCO1     US Nested CC 
 PLCO2    US Nested CC 
 PMH      US Pop. CC 
 VITAL     US Nested CC 
 WHI1      US Nested CC 
 WHI2      US Nested CC 
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Supplementary table 2. Gene- and pathway-based p-values for overall and aggressive prostate cancer 
   Combined results  Aggressive prostate 
  
(14818 cases, 14227 
controls)  
(up to 4446 cases, 12724 
controls) 
Gene Chr N.SNPs P-value   N.SNPs P-value 
Circadian rhythm pathway     
ARNTL 11 80 0.29  80 0.54 
CK1E 22 48 0.30  48 0.58 
CLOCK 4 24 0.021  24 0.093 
CRYI 12 35 0.55  35 0.87 
CRY2 11 20 0.043  20 0.57 
NPAS2 2 167 0.0062  167 0.18 
PER1 17 30 0.063  30 0.70 
PER2 2 50 0.060  50 0.23 
PER3 1 67 0.24  67 0.030 
Pathway-level 521 0.0016*   521 0.29 
       
Melanotin pathway      
AANAT 17 38 0.00078*  38 0.47 
DDC 7 84 0.050  84 0.49 
MTNR1A 4 35 0.35  35 0.22 
MTNR1B 11 23 0.96  23 0.32 
TPH1 11 18 0.15  18 0.96 
TPH2 12 65 0.21  65 0.35 
Pathway-level  263 0.0060*   263 0.66 
*Statistically significant after Bonferroni correction (p < 0.05/8=0.00625 at pathway level; p < 0.05/60=0.00083 at gene level) 
P<0.05 in bold 
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Supplementary Table 3. Comparison of SNP-based results between overall and aggressive prostate cancer*  
  Allele Overall Aggressive 
Gene SNP* Ref** Eff** log(OR) SE P-value log(OR) SE P-value 
Circadian rhythm pathway 
CLOCK rs62309758 T C -0.09 0.03 1.45E-03 -0.09 0.04 7.57E-03 
CRY2 rs7108730 T C 0.08 0.03 3.66E-03 0.06 0.04 1.05E-01 
NPAS2 rs2305160 A G 0.08 0.02 3.47E-05 0.06 0.03 3.00E-02 
Melatonin pathway 
AANAT rs150316415 G A 0.28 0.07 3.41E-05 0.16 0.08 6.49E-02 
DDC rs12718611 G A -0.11 0.04 1.72E-03 -0.07 0.05 1.12E-01 
*SNPs with the smallest p-value in the genes with Pgene≤0.05, based on association with overall prostate cancer. 
**reference and effect alleles 
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Supplementary table 4. Gene- and pathway-based p-values for colorectal cancer in GAME-ON and replication samples 
    Game-ON (CORECT)   GECCO     Combined results 
  (5100 cases, 4831 controls)  (10738 cases, 13328 controls)  (15838 cases, 18159 controls) 
Gene Chr N.SNPs P-value   N.SNPs P-value   N.SNPs P-value 
Circadian rhythm pathway        
ARNTL 11 114 0.0044  113 0.78  140 0.028 
CK1E 22 38 0.14  55 0.18  68 0.24 
CLOCK 4 47 0.18  35 0.34  53 0.11 
CRYI 12 56 0.81  47 0.83  73 0.95 
CRY2 11 35 0.64  32 0.85  41 0.91 
NPAS2 2 202 0.011  212 0.82  245 0.51 
PER1 17 47 0.60  38 0.44  53 0.55 
PER2 2 54 0.63  54 0.40  68 0.59 
PER3 1 60 0.68   84 0.15   101 0.047 
Pathway-level   653 0.021   670 0.76   842 0.17 
          
Melatonin pathway         
AANAT 17 53 0.59  52 0.85  61 0.91 
DDC 7 119 0.89  115 0.58  147 0.74 
MTNR1A 4 60 0.18  61 0.86  72 0.30 
MTNR1B 11 33 0.92  34 0.87  45 0.96 
TPH1 11 20 0.029  22 0.27  27 0.068 
TPH2 12 67 0.77   92 0.0064   107 0.013 
Pathway-level 352 0.24   376 0.066   459 0.091 
 P<0.05 in bold. None of gene based or pathway based p values reached Bonferroni corrected significance  
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Supplementary table 5. Gene- and pathway-based p-values for lung and ovarian cancers in GAME-ON 
   
Lung cancer 
(12537 cases, 17285 controls)  
Ovarian cancer 
(4369 cases, 9123 controls) 
Gene Chr   N.SNP* P-value   N.SNP* P-value 
Circadian rhythm pathway 
ARNTL 11  78 0.18  80 0.58 
CK1E 22  47 0.35  48 0.024 
CLOCK 4  24 0.19  24 0.20 
CRYI 12  33 0.40  35 0.29 
CRY2 11  18 0.52  20 0.13 
NPAS2 2  165 0.56  167 0.046 
PER1 17  29 0.35  30 0.87 
PER2 2  50 0.87  50 0.54 
PER3 1   66 0.90   67 0.68 
Pathway-level   510 0.71   521 0.14 
Melatonin pathway       
AANAT 17  30 0.63  38 0.14 
DDC 7  82 0.089  84 0.10 
MTNR1A 4  35 0.93  35 0.20 
MTNR1B 11  21 0.85  23 0.64 
TPH1 11  17 0.23  18 0.21 
TPH2 12   58 0.048   65 0.75 
Pathway-level   243 0.22   263 0.26 
*SNP numbers after the LD pruning, using r2>0.95 
P<0.05 in bold. None of gene- or pathway-level p-values reached the Bonferroni correction threshold of significance.  
